Allergic contact dermatitis from topical ophthalmic medications: keep an eye on it!
Liesbeth Gilissen Lana Dedecker Toon Hulshagen An Goossens
First published: 10 January 2019 https://doi.org/10.1111/cod.13209
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cod.13209.
PDFTOOLS SHARE
Abstract
Background
Allergic contact dermatitis (ACD) from topical ophthalmic medications is often overlooked.
Objectives
To study the demographic characteristics, lesion locations, and associated medical conditions of the patients with ACD from ophthalmic drugs, and to identify the most common allergenic culprits, as well as trends in frequencies over the years.
Methods
From January 1990 until December 2016, 16 065 patients were investigated in our clinic; all patients with a positive patch‐test reaction to eye medication or its ingredient(s) having caused ACD were studied. For each allergen identified, the number of positive test results compared with the total number of those in the total population, as well as trends across three periods, namely 1990‐1998, 1999‐2007, and 2008‐2016 were studied.
Results
118 patients (0.7%) presented with positive patch‐test results to ingredients of, and/or topical ophthalmic medications. Aminoglycoside antibiotics, followed by corticosteroids, as pharmacologically active ingredients, as well as wool alcohols, thiomersal and benzalkonium chloride, as excipients were the most frequent culprits. Particularly chloramphenicol showed a decreasing trend in positive reactions over time, whereas reactions tobramycin were increasing.
Conclusion
ACD from eye medication is mainly due to active principles, but other excipient ingredients, beside the products "as is", should be tested as well.
https://onlinelibrary.wiley.com/doi/10.1111/cod.13209
Liesbeth Gilissen Lana Dedecker Toon Hulshagen An Goossens
First published: 10 January 2019 https://doi.org/10.1111/cod.13209
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cod.13209.
PDFTOOLS SHARE
Abstract
Background
Allergic contact dermatitis (ACD) from topical ophthalmic medications is often overlooked.
Objectives
To study the demographic characteristics, lesion locations, and associated medical conditions of the patients with ACD from ophthalmic drugs, and to identify the most common allergenic culprits, as well as trends in frequencies over the years.
Methods
From January 1990 until December 2016, 16 065 patients were investigated in our clinic; all patients with a positive patch‐test reaction to eye medication or its ingredient(s) having caused ACD were studied. For each allergen identified, the number of positive test results compared with the total number of those in the total population, as well as trends across three periods, namely 1990‐1998, 1999‐2007, and 2008‐2016 were studied.
Results
118 patients (0.7%) presented with positive patch‐test results to ingredients of, and/or topical ophthalmic medications. Aminoglycoside antibiotics, followed by corticosteroids, as pharmacologically active ingredients, as well as wool alcohols, thiomersal and benzalkonium chloride, as excipients were the most frequent culprits. Particularly chloramphenicol showed a decreasing trend in positive reactions over time, whereas reactions tobramycin were increasing.
Conclusion
ACD from eye medication is mainly due to active principles, but other excipient ingredients, beside the products "as is", should be tested as well.
https://onlinelibrary.wiley.com/doi/10.1111/cod.13209
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.